Skip to main content

Month: March 2022

Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree

-Transaction Provides Immediate, Non-Dilutive Capital to Further Support Commercialization of Trudhesa™ -$100 million in gross proceeds to be funded at close, extending estimated corporate cash runway into 2024 SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) — Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced two separate transactions with funds managed by Oaktree Capital Management, L.P. (“Oaktree”) totaling $100 million in gross funding. The transactions include a $50 million royalty agreement on net sales of the nasal spray, Trudhesa™, and $50 million of senior secured debt. Based on current projections, these funds provide Impel with a...

Continue reading

AMMO, Inc. Announces Plans to Provide Crypto Currency Processing Capabilities for GunBroker.com

SCOTTSDALE, Ariz., March 17, 2022 (GLOBE NEWSWIRE) — AMMO, Inc. (Nasdaq: POWW, POWWP) (“AMMO” or the “Company”), owner of GunBroker.com, the largest online marketplace serving the firearms and shooting sports industries, and a leading vertically integrated producer of high-performance ammunition and components, today announced an agreement with Digital Cash Processing to provide digital payment solutions for transactions on GunBroker.com Digital Cash Processing (“DCP”), a unit of Prior Lake, Minnesota-based Innovative Computer Professionals Inc., is a leading fintech corporation providing single source solutions for global issuing and acquiring including ATM, POS, e-commerce and crypto currency processing. Fred Wagenhals, AMMO Chairman & CEO, commented on this exciting business partnership, noting that “AMMO is taking a significant...

Continue reading

Integer Announces Board Leadership Transition

PLANO, Texas, March 17, 2022 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource (MDO) manufacturer, announced today that Bill R. Sanford will be retiring as Chair of the Integer Board of Directors at the conclusion of the Company’s 2022 annual meeting of stockholders, which is scheduled to be held on May 18, 2022. Commensurate with this carefully planned transition, the Board of Directors plans to appoint current long-standing Integer Board member Pamela G. Bailey to serve as the next Chair of the Board. “On behalf of the Integer Board of Directors, I wish to thank Bill for his immense contribution and insightful leadership over the past 22 years serving on the Integer Board, including his 14 years as Board Chair,” said Joe Dziedzic, Integer’s President and CEO. “Bill has positioned...

Continue reading

Multinational Semiconductor Company Orders Multiple VEECO Wet Processing Systems for Advanced Packaging Applications

PLAINVIEW, N.Y., March 17, 2022 (GLOBE NEWSWIRE) — Veeco Instruments Inc. (NASDAQ: VECO) today announced that a world-leading semiconductor manufacturer has ordered multiple Veeco WaferStorm® Wet Processing Systems for advanced packaging applications. The systems were chosen due to the low cost of ownership advantage and process performance compared to other platforms. The customer also operates Veeco’s LSA201 Laser Spike Annealing System for their front-end-of-line processes and AP300 Lithography Systems for advanced packaging. “We are proud to have been selected by yet another world-leading semiconductor manufacturer for our wet processing technology,” commented Adrian Devasahayam, Ph.D., Senior Vice President, Product Line Management. “The WaferStorm platform consistently demonstrates low chemistry usage driving low operating...

Continue reading

PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022

TEL AVIV, Israel, March 17, 2022 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2021. Ilan Hadar, Chief Executive Officer, stated, “We remain on track to commence our Phase 3 clinical trial of PRF-110 in bunionectomy in the second half of 2022. Specifically, we are advancing the manufacturing of PRF-110 clinical batches with our partner Pharmaceutics International, Inc. (PII), a U.S.-based contract manufacturing organization (CMO). After completion of the first trial, we plan to initiate the Phase 3 hernia repair clinical trial based on a similar study design to the prior Phase 2 trial. According to...

Continue reading

Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis

WARREN, N.J., March 17, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AQST-109, the first and only orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions, including anaphylaxis. “We are focused on continuing to develop and, if approved, bringing this transformative product to patients and caregivers given its potential to significantly improve how they manage anaphylaxis,” said Keith Kendall, Chief Executive Officer of Aquestive. “Fast Track designation is an indication that the FDA recognizes...

Continue reading

AYRO to Report Year-End 2021 Financial Results on Wednesday, March 23, 2022 and Provide Corporate Update

Conference Call to be held Wednesday, March 23, 2022 at 8:30 a.m. Eastern Time ROUND ROCK, TX, March 17, 2022 (GLOBE NEWSWIRE) — AYRO, Inc. (Nasdaq: AYRO) (“AYRO” or the “Company”), a designer and manufacturer of electric, purpose-built delivery vehicles and solutions for micro distribution, micro mobility, and last-mile delivery, announces that it will report year-end 2021 financial results on Wednesday, March 23, 2022 before the market open. AYRO management will also host a conference call at 8:30 a.m. ET on Wednesday, March 23, 2022 to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.To listen to the conference call, interested parties within the U.S. should dial 1-833-953-2436 (domestic) or 1-412-317-5765 (international)....

Continue reading

BIO-key Showcases Higher Education IAM Solutions and Expertise at California Community College Tech Summit March 20-23 – Booth 405; Customers Host Sessions on their Success with PortalGuard Platform

ONTARIO, Calif. and WALL, N.J., March 17, 2022 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of Identity and Access Management (IAM) and Identity-Bound Biometric (IBB) solutions, today announced it will be a sponsor and exhibitor at the 2022 Chief Information Systems Officers Association (CISOA) Technology Summit, part of the California Community College (CCC) system, to be held at the Ontario Convention Center in Ontario, California March 20-23. BIO-key will be available for customer meetings to discuss migrating to the cloud, Q&A sessions, and live demonstrations of their award-winning PortalGuard platform in booth 405. Three of BIO-key’s CCC customers, College of the Canyons, Ventura County Community College District, and Allan Hancock College, will conduct seminars as part of the...

Continue reading

Decisions taken at Cargotec’s Annual General Meeting 2022

CARGOTEC CORPORATION, STOCK EXCHANGE RELEASE, 17 MARCH 2022 AT 1:45 PM (EET) Decisions taken at Cargotec’s Annual General Meeting 2022 Cargotec Corporation’s Annual General Meeting was held today 17 March 2022 in Helsinki, Finland. The Annual General Meeting approved a distribution of a dividend of EUR 1.07 for each of class A shares and a dividend of EUR 1.08 for each outstanding class B shares. The dividend shall be paid to shareholders who on the record date of dividend distribution, 21 March 2022, are registered as shareholders in the company’s shareholder register. The dividend payment day is 28 March 2022. The meeting adopted the financial statements and consolidated financial statements and approved the remuneration report. The meeting granted discharge from liability to the CEO and the members of the Board of...

Continue reading

Platinex Announces Further Expansion of W2 Copper-Nickel-PGE Project

TORONTO, March 17, 2022 (GLOBE NEWSWIRE) — Platinex Inc. (CSE: PTX) (Frankfurt: 9PX) (“Platinex” or the “Company”) is pleased to announce that its wholly owned subsidiary, Endurance Elements Inc. (“Endurance Elements”) has acquired 149 mining claims located along the western boundary of the W2 Copper-Nickel-PGE Project (the “W2 Project” or “W2”) in Ontario’s Ring of Fire (see press releases dated January 17, 2022 and January 27, 2022). The additional 2,932 hectares (29.3 km2) of ground brings the W2 land package to 15,973 hectares (159.7 km2). Endurance Elements holds a 100% interest in the W2 Project. The W2 Project now covers approximately 80% of the layered mafic-ultramafic Lansdowne House Igneous Complex (“LHIC”) which is highly prospective for copper-nickel (Cu-Ni) and reef-type platinum group element (PGE) deposits. The widespread...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.